Cohen Yuval 4

What Happened
Yuval Cohen, CEO of Corbus Pharmaceuticals (CRBP), disposed of 13,871 shares on February 13, 2026 in transactions with a weighted average price of $7.78, generating approximately $107,952 in proceeds. The sale was effected under a Rule 10b5-1 trading plan and was a "sell-to-cover" to satisfy tax withholding obligations related to the vesting and settlement of RSUs, not a discretionary sale.

Key Details

• Transaction date: February 13, 2026. Form 4 filed February 18, 2026 (appears timely under the 2-business-day rule).
• Transaction type/code: Sale (S) — open market or private sale, multiple trades.
• Prices: Weighted average $7.78; individual trades ranged $7.58–$7.96 (report provides weighted avg and range; breakdown available on request).
• Proceeds: Approximately $107,952.
• Holdings: The filing notes the reported holdings include 138,049 unvested RSUs subject to prior vesting schedules; the filing does not specify a separate total beneficial ownership number in the summary provided here.
• Footnotes: F1 — sale pursuant to 10b5-1 plan and mandated by issuer's sell-to-cover election for RSU tax withholding (non-discretionary). F2 — weighted average price and price range; seller will provide per-price breakdown on request. F3 — reference to 138,049 unvested RSUs.

Context
This was a routine sell-to-cover tied to RSU vesting and executed under a pre-established 10b5-1 plan, which typically reflects tax-related mechanics rather than a CEO decision to reduce exposure. For retail investors, mandatory sell-to-cover transactions carry less informational weight about management’s view of the company compared with voluntary open-market purchases.